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Background: Chronic renal failure is the progressive loss of kidney function. 
Patients use long treatment in the form of renal replacement therapy.    
Hemodialysis is one of the renal replacement therapy, during which body’s waste 
products, including creatinine, urea and excess water as well as excess electrolytes 
are removed. Patients with chronic renal failure CRF suffer from lipid 
abnormalities. This study aimed to evaluate lipid profile and creatinine clearance in 
hemodialysis patients in Aldamazin city, Blue Nile State.  
Patient’s and methods:  This is a hospital based cross-sectional descriptive study 
was conducted on forty two ESRD patients on maintenance hemodialysis. Data 
were obtained by using questionnaire and laboratory investigations. Blood samples 
(5 ml) were analyzed for Lipid profile pre and post hemodialysis. Creatinine and 
urea were measured pre and post hemodialysis and then creatinine clearance was 
calculated. Enzymatic method was used to estimate serum lipid profile by using 
Mindary analyzer  BS-200, and results data were analyzed using (SPSS version 24) 
computer program (two T- test and ANova test). 
Result:  There was a significant increase in lipid profile indices in ESRD patients 
post hemodialysis compared with pre hemodialysis (P<0.00). In addition, there was 
significant associated between Cholesterol, TG and LDL in pre hemodialysis and 
hemodialysis duration (P<0.00). There was significant differences between 
Cholesterol, TG, LDL and VLDL in post hemodialysis and hemodialysis duration 
(P<0.00). Significance differences was found between Cholesterol, TG, LDL and 
VLDL in pre and post hemodialysis values (P<0.00).  
Conclusion: Our present study concluded that, hemodialysis leads to significant 
changes in the lipid profile indices and renal function markers. In addition, there is 
significant difference between cholesterol, TG and LDL (pre and post 
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hemodialysis) and hemodialysis duration. There is significant association between 





















ﺘﺎج ﻟﻠﻌﻼج  ﻟﻔﺘﺮة زﻣﻨﯿﺔ ﺤ:اﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﻤﺰﻣﻦ ھﻮ اﻟﻔﻘﺪان اﻟﺘﺪرﯾﺠﻲ ﻟﻮظﺎﺋﻒ اﻟﻜﻠﻰ ، واﻟﻤﺮﯾﺾ ﯾ اﻟﺨﻠﻔﯿﺔ
ﻏﺴﯿﻞ اﻟﻜﻠﻰ ھﻮ واﺣﺪ ﻣﻦ اﻟﻌﻼج اﻟﺒﺪﯾﻞ اﻟﻜﻠﻮي، واﻟﺬى ﯾﺘﻢ ﺧﻼﻟﮫ وطﻮﯾﻠﮫ ﻓﻲ ﺷﻜﻞ اﻟﻌﻼج اﻟﺒﺪﯾﻞ اﻟﻜﻠﻮي. 
ﻜﺮﯾﺎﺗﯿﻨﯿﻦ واﻟﯿﻮرﯾﺎ واﻟﻤﯿﺎه اﻟﺰاﺋﺪة، واﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن إزاﻟﺔ اﻟﻨﻔﺎﯾﺎت واﻟﻤﺨﻠﻔﺎت ﻣﻦ اﻟﺠﺴﻢ، ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻟ
 ﻣﻦ اﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﻤﺰﻣﻦ ﯾﻌﺎﻧﻮن ﻣﻦ إﺿﺮاﺑﺎت اﻟﺪھﻮن. 
ھﺪﻓﺖ ھﺬه اﻟﺪراﺳﺔ إﻟﻰ ﺗﻘﯿﯿﻢ اﻻرﺗﺒﺎط ﺑﯿﻦ اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺪھﻨﯿﺔ وﺗﺼﻔﯿﺔ اﻟﻜﺮﯾﺎﺗﯿﻨﯿﻦ ﻟﺪي ﻣﺮﺿﻰ اﻟﻜﻠﻰ ﻓﻲ 
 ﻮي ﻟﻠﻜﻠﻰ.اﻟﻤﺮﺣﻠﺔ اﻟﻨﮭﺎﺋﯿﺔ  ﻟﻠﻤﺮض  واﻟﺬﯾﻦ ﯾﺨﻀﻌﻮن ﻟﻸﺻﻄﺼﻔﺎء اﻟﺪﻣ
أﺟﺮﯾﺖ ھﺬه اﻟﺪراﺳﺔ ﺑﮭﺪف دراﺳﺔ ﺗﺎﺛﯿﺮ اﻻﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي ﻋﻠﻲ ﺗﺮﻛﯿﺰ وﻣﺴﺘﻮي  :ﻮاﺳﺎﺋﻞواﻟ اﻟﻤﺮﺿﻲ
اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺪھﻨﯿﺔ و ﺗﺼﻔﯿﺔ اﻟﻜﺮﯾﺎﺗﻨﯿﻦ اﻟﻤﺴﺘﻨﺪة إﻟﻰ اﻟﺪراﺳﺔ اﻟﻮﺻﻔﯿﺔ واﻟﺮﺻﺪ ﻓﻲ اﻟﻤﺴﺘﺸﻔԩﺎت ﻋﻠﻰ اﺛﻨﯿﻦ 
اﻟﻜﻠﻰ و اﻟﺬﯾﻦ ﯾﺨﻀﻌﻮن ﻟﻸﺻﻄﺼﻔﺎء وارﺑﻌﻮن ﻣﺮﯾﻀﺎ ﺳﻮداﻧﯿﺎ ً ﻓﻲ  اﻟﻤﺮﺣﻠﺔ اﻟﻤﺮﺿﯿﺔ اﻟﻨﮭﺎﺋﯿﺔ ﻣﻦ أﻣﺮاض 
اﻟﺪﻣﻮي ﻟﻠﻜﻠﻰ . ﺗﻢ اﻟﺤﺼﻮل ﻋﻠﻰ اﻟﺒﯿﺎﻧﺎت ﺑﺎﺳﺘﺨﺪام اﻻﺳﺘﺒﯿﺎن واﻟﺘﺤﻠﯿﻼت اﻟﻤﺨﺘﺒﺮﯾﺔ. ﺗﻢ ﺗﺤﻠﯿﻞ اﻟﺒﺮوﺗﯿﻨﺎت 
 واﻟﺠﻠﯿﺴﺮﯾﺪ اﻟﻜﻮﻟﯿﺴﺘﺮول ﻋﻠﻲ اﺷﺘﻤﻠﺖ اﻟﺪم ﻓﻲ ﺗﺤﻠﯿﻠﮭﺎ ﺗﻢ اﻟﺘﻲ . اﻟﺪھﻮن اﻟﺪھﻨﯿﺔ وﺗﻢ ﺣﺴﺎب ﺗﺼﻔﯿﺔ اﻟﻜﺮﯾﺎﺗﯿﻨﯿﻦ
 ﻗﻠﯿﻞ اﻟﺒﺮوﺗﯿﻦ ﻓﻲ اﻟﺪھﻨﻲ اﻻﺿﻄﺮاب ، اﻟﻜﺜﺎﻓﺔ ﻗﻠﯿﻞ اﻟﺒﺮوﺗﯿﻦ ﻓﻲ اﻟﺪھﻨﻲ ﺮاب،اﻻﺿﻄ اﻟﺪھﻮن ﻓﻲ اﻟﺜﻼﺛﻲ
 .اﻟﻜﺜﺎﻓﺔ ﻣﺮﺗﻔﻊ اﻟﺒﺮوﺗﯿﻦ ﻓﻲ اﻟﺪھﻨﻲ ،اﻻﺿﻄﺮاب ﺟﺪا اﻟﻜﺜﺎﻓﺔ
وﺟﺪت زﯾﺎدة ذات دﻻﻟﮫ اﺣﺼﺎﺋﯿﺔ ﻓﻲ ﻣﺴﺘﻮي اﻟﻜﻮﻟﯿﺴﺘﺮول اﻟﻜﻠﻲ واﻟﺪھﻮن اﻟﺜﻼﺛﯿﺔ ﻓﻲ اﻟﺪم ﻟﺪي  :ﺎﺋﺞاﻟﻨﺘ
اﻹﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي  ﻣﻘﺎرﻧﺔ ﻣﻊ ﻧﻔﺲ اﻟﻤﺮﺿﻲ اﯾﻀﺎ وﺟﺪت زﯾﺎدة ﻣﺮﺿﻰ اﻟﻜﻠﻲ ﻓﻲ اﻟﻤﺮﺣﻠﺔ اﻟﻨﮭﺎﺋﯿﺔ ﻗﺒﻞ 
ذات دﻻﻟﺔ اﺣﺼﺎﺋﯿﺔ ﺑﻌﺪ اﻹﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي . وﺟﺪ ھﻨﺎك اﻧﺨﻔﺎض ﻛﺒﯿﺮ ﻓﻲ ﻣﺴﺘﻮﯾﺎت اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻋﺎﻟﻲ 
ﻧﻔﺲ اﻟﻤﺮﺿﻰ ﺑﻌﺪ  اﻟﻜﺜﺎﻓﺔ اﻟﻜﻮﻟﺴﺘﺮول ﻓﻲ اﻟﻤﺮﺿﻰ  ﻗﺒﻞ وﺑﻌﺪ اﻷﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي ﺑﺎﻟﻤﻘﺎرﻧﺔ ﻣﻊ
ان ﻣﺴﺘﻮﯾﺎت  اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻗﻠﯿﻞ اﻟﻜﺜﺎﻓﺔ  واﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻗﻠﯿﻞ اﻟﻜﺜﺎﻓﺔ ﺟﺪا ً  اﻷﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي . وﺟﺪت
زادت ﺑﺸﻜﻞ ﻣﻠﺤﻮظ ﻗﺒﻞ وﺑﻌﺪ اﻷﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي . وﺟﺪ إﻧﺨﻔﺎض ذا دﻻﻟﺔ اﺣﺼﺎﺋﯿﺔ ﻓﻲ ﻣﺆﺷﺮ ﻛﺘﻠﺔ اﻟﺠﺴﻢ  
 ﺑﻌﺪ ﺟﻠﺴﺔ اﻷﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي ﻟﺪي اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺨﻀﻌﻮن ﻟﻸﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي . وﺟﺪت زﯾﺎدة  ﺑﺸﻜﻞ
ﻣﻠﺤﻮظ ﻓﻲ ﻣﺴﺘﻮﯾﺎت ﺗﺼﻔﯿﺔ اﻟﻜﺮﯾﺎﺗﯿﻨﯿﻦ  ﺑﻌﺪ ﺟﻠﺴﺔ اﻷﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي ﻟﺪي اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺨﻀﻌﻮن 
 ﻟﻸﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي . 
 واﻟﻔﺘﺮة اﻟﺰﻣﻨﯿﺔ ﻟﻼﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي اﻟﻜﺜﺎﻓﺔ ﻗﻠﯿﻞ اﻟﺪھﻨﻲ اﻻﺿﻄﺮاب ﻋﻼﻗﺔ إﯾﺠﺎﺑﯿﺔ ﺑﯿﻦ وﺟﺪت اﻟﺨﻼﺻﺔ:
 ﻣﻌﺪل ﻧﺴﺒﺔ ان اﯾﻀﺎ واﺗﻀﺢ . اﻟﻜﺜﺎﻓﺔ ﻞﻗﻠﯿ اﻟﺪھﻨﻲ اﻻﺿﻄﺮاب ﻣﻌﺪل ﯾﺰﯾﺪ ﺗﺰﯾﺪ اﻟﻔﺘﺮة اﻟﺰﻣﻨﯿﺔ ﻋﻨﺪﻣﺎ
 . اﻟﻔﺘﺮة اﻟﺰﻣﻨﯿﺔ ﻟﻸﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي  ﯾﻨﻘﺺ ﺑﺰﯾﺎدة اﻟﻤﺮض و ﻣﺪة ﺑﺰﯾﺎدة ﯾﺰﯾﺪ اﻟﻜﻠﯿﺴﺘﺮول
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ﻧﺘﺎﺋﺞ ھﺬة اﻟﺪراﺳﺔ ﻗﺪ اﺗﻔﻘﺖ ﻣﻊ ﻋﺪد ﻣﻦ اﻟﺪراﺳﺎت اﻟﺴﺎﺑﻘﺔ ﻓﻲ اﻻﺿﺮاب اﻟﺪھﻨﻲ ﻋﻨﺪ اﻟﻤﺮﺿﻲ اﻟﻤﺼﺎﺑﯿﻦ 
 ﺑﺎﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﻤﺰﻣﻦ .
ﺗﺄﺛﯿﺮ اﻻﺻﻄﺼﻔﺎء اﻟﺪﻣﻮي ﻓﻲ ارﺗﻔﺎع  واﻧﺨﻔﺎض ﺑﻌﺾ اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺪھﻨﯿﺔ ھﺬه اﻟﺪراﺳﺔ ﺗﻌﻜﺲ ﺑﻮﺿﻮح 
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